NCT01734447 is a Phase 4 clinical trial of somatropin in Foetal Growth Problem, sponsored by Novo Nordisk A/S.

Who is sponsoring NCT01734447?

NCT01734447 is sponsored by Novo Nordisk A/S.

What drugs are being tested in NCT01734447?

Interventions in NCT01734447: somatropin, somatropin, somatropin.

What condition does NCT01734447 study?

NCT01734447 studies Foetal Growth Problem, Small for Gestational Age.

Is NCT01734447 still recruiting?

NCT01734447 is currently completed. Last updated 28 February 2017.

Last reviewed 2017-02-28 · How we verify

NCT01734447

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

Long Term Effect of Somatropin in Subjects With Intrauterine Growth Retardation

Completed Phase 4 Last updated 28 February 2017

What this trial tests

Phase 4 trial testing somatropin in Foetal Growth Problem in 57 participants. Completed in 30 April 2003.

Timeline

30 April 2000

Primary endpoint
30 April 2003

30 April 2003

Quick facts

Lead sponsor	Novo Nordisk A/S
Phase	Phase 4
Status	Completed
Study type	INTERVENTIONAL
Allocation	randomized
Design	parallel
Masking	none
Primary purpose	treatment
Enrollment	57
Start date	30 April 2000
Primary completion	30 April 2003
Estimated completion	30 April 2003
Sites	1 location across France

Drugs / interventions tested

somatropin (Somatropin) — full drug profile →
somatropin (Somatropin) — full drug profile →
somatropin (Somatropin) — full drug profile →

Conditions studied

Foetal Growth Problem — all drugs for Foetal Growth Problem →
Small for Gestational Age — all drugs for Small for Gestational Age →

Sponsor

Novo Nordisk A/S — full company profile →

Who can join

Eligibility, any sex, with Foetal Growth Problem or Small for Gestational Age. Patients with the condition only — healthy volunteers not accepted.

Sponsor's own description

This trial is conducted in Europe. The aim of this trial is to assess the safety of long-term growth hormone treatment in growth-retarded children with intrauterine growth retardation (IUGR) enrolled in trial GHRETARD/F/1/F.

Publications & conference data

No peer-reviewed publications indexed yet for this trial. Completed trials usually publish results within 12-18 months.

Verify or expand the search:

Other trials of somatropin

Trials testing the same drug.

NCT02726542 — Augmenting Growth Hormone to Ameliorate Nonalcoholic Fatty Liver Disease in Adolescents · EARLY_PHASE1 · completed
NCT02382939 — A Trial to Compare the Safety of Once Weekly Dosing of Somapacitan With Daily Norditropin® FlexPro® for 26 Weeks in Prev · Phase 3 · completed
NCT02229851 — Trial to Compare the Efficacy and Safety of NNC0195-0092 (Somapacitan) With Placebo and Norditropin® FlexPro® (Somatropi · Phase 3 · completed
NCT02092077 — A Phase 2, Safety and Dose-Finding Study in Treatment-Naive, Pre-Pubertal, Growth Hormone-Deficient Children · Phase 2 · terminated
NCT01973244 — A Trial Investigating Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of a Single Dose of Long-acting Growth · Phase 1 · completed

Other Novo Nordisk A/S trials

Trials by the same sponsor.

NCT07357740 — A Research Study to Compare Two Different Versions of Injectable CagriSema in People With Type 2 Diabetes · Phase 2 · not yet recruiting
NCT07282613 — A Research Study to See How Much CagriSema Lowers Blood Sugar and Body Weight Compared to Placebo in Children and Adoles · Phase 3 · not yet recruiting
NCT07357766 — A Research Study to Compare Different Versions of Injectable CagriSema and Placebo in People With Excess Body Weight · Phase 3 · not yet recruiting
NCT07564414 — A Research Study to Look at How Two Different Doses of CagriSema and One Dose of Semaglutide Help People Living With Obe · Phase 3 · not yet recruiting
NCT07400107 — AMAZE 8: A Research Study Investigating How Well the Medicine NNC0487-0111 Compared to Semaglutide Helps People With Exc · Phase 3 · not yet recruiting

Verify against primary sources

ClinicalTrials.gov — authoritative US registry record
WHO ICTRP — international registry index
EU Clinical Trials Register
Sponsor press releases (Google)

Data sources for this page

Trial protocol + status: ClinicalTrials.gov NCT01734447 (US National Library of Medicine, public domain)
Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
Sponsor: as reported to ClinicalTrials.gov by Novo Nordisk A/S
Last refreshed: 28 February 2017

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT01734447.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing